HK Stock Market Move | BBMG Corporation (02009) rises by over 6%. Bbmg Jidong Cement Group Co., Ltd.'s 9000t/d cement clinker production line is planned to start operation next year.
China Jinmao Holdings Group (02009) rose more than 6%, as of the time of publication, it increased by 4.88%, reaching 0.87 Hong Kong dollars, with a turnover of 46.66 million Hong Kong dollars.
BBMG Corporation (02009) rose more than 6%, rising to 4.88% at the time of writing, at a price of 0.87 Hong Kong dollars, with a turnover of 46.6626 million Hong Kong dollars.
On the news front, according to Cement Network, the Department of Industry and Information Technology of Hebei Province recently issued a notice listing key construction projects in the province for the year 2026. Among them is the relocation project of the Handan Jinyu Taihang 24500t/d cement kiln collaborative disposal of solid waste production line (Fengfeng Mining Area). The Department of Industry and Information Technology of Hebei Province previously announced that the Handan Jinyu relocation project will integrate and upgrade the originally planned 24500t/d cement clinker production line into a single 9000t/d production line. The replacement plan shows that the project will exit production capacity from the same company's 2000t/d, 2500t/d, and 4500t/d production lines, with a replacement ratio of 1:1. The planned construction start date is January 1, 2026, and the planned start-up production date is June 30, 2027.
Related Articles
.png)
HK Stock Market Move | SINO BIOPHARM(01177) rises more than 4%, management is optimistic about the prospects of VIIa being included in insurance coverage. The drug is developed by its subsidiary, Zhongda Tianqing.

HK Stock Market Move | IMMUNEONCO-B(01541) rose by more than 10% in early trading. IMM01 has been approved for clinical trials for the treatment of atherosclerosis.

Furui: Lower target price of LAOPU GOLD (06181) to 981 Hong Kong dollars. High gold prices suppress gross profit.
HK Stock Market Move | SINO BIOPHARM(01177) rises more than 4%, management is optimistic about the prospects of VIIa being included in insurance coverage. The drug is developed by its subsidiary, Zhongda Tianqing.
.png)
HK Stock Market Move | IMMUNEONCO-B(01541) rose by more than 10% in early trading. IMM01 has been approved for clinical trials for the treatment of atherosclerosis.

Furui: Lower target price of LAOPU GOLD (06181) to 981 Hong Kong dollars. High gold prices suppress gross profit.

RECOMMEND

Patent Cliff Looms As Pharmaceutical Sector Prepares For A New Round Of Asset Competition
10/01/2026

Goldman Sachs Remains Bullish On China Equities: AI And Overseas Expansion To Drive Earnings, MSCI China Seen Rising 20% In 2026
10/01/2026

“A+H” Popularity Continues As Multiple A‑Share Companies Announce Hong Kong Listings At The Start Of The Year
10/01/2026


